Investor resources

Why Invest?

Investment Highlights

cold laser therapy technology
Proven Technology

Patented light-activated Photo Dynamic Compounds ("PDCs") have been clinically proven to destroy NMIBC and allow patients to achieve a complete response (cancer-free)

cold laser therapy milestones
Near-Term Milestones

Phase II NMIBC clinical study is in progress with University Health Network ("UHN") ( Toronto, Ontario), McGill University Health Centre ("MUHC") (Montreal, Quebec), London Health Sciences Centre ("LHSC")( London, Ontario) and Nova Scotia Health Authority ("NSHA") (Halifax, Nova Scotia) currently enrolling and treating patients. This clinical study sites have successfully enrolled and treated 12 patients in a planned 100 patient pivotal Phase II clinical study.

laser therapy theralase management team
Experienced Management Team

Our experienced management team has partnered with leading scientific and clinical researchers from renowned research hospitals and academic institutions to develop cutting-edge technologies to destroy cancer and eliminate pain.

laser therapy for pain clinical stage
Clinical Stage Company

Theralase®’s patented TLD-1433 PDC has successfully completed a Phase 1b NMIBC clinical study demonstrating strong safety and a 67% Complete Response rate.

cold laser therapy theralase record of sucess
Proven Track Record of Success

For over 25 years, Theralase® has focused on the research, development and commercialization of patented and proprietary laser technologies.

cold laser therapy theralase
Strong Intellectual Property Portfolio

Theralase® has been issued 27 patents for its technology and has an additional 27 patents pending.

Words from the CEO

“Theralase® with a mandate to commercialize our cutting-edge Anti-Cancer Therapy (“ACT”), has advanced to a pivotal Phase II clinical study, which if proven successful, will realize this dream. Our clinical research team is working diligently on patient enrollment and treatment of patients at select Canadian and US clinical study sites, when launched. If Study II is completed successfully, Theralase® will have an opportunity to be the next gold standard for patients with NMIBC. We believe we can bring hope for the future!”Shawn Shirazi, Ph.D.| Chief Executive Officer

Corporate Presentation

theralase testimonials

Fact Sheet

clinical research PDT

Quarterly Newsletters

about theralase

Financial Filings

investor information

Press Releases


Contact Information

Transfer Agent:

TMX Equity Transfer Services Inc.

100 Adelaide Streety West, Suite 301,
Toronto, Ontario

Work: 416-361-0930


Richter LLP

181 Bay Street, Suite 3510
Bay Wellington Tower
Toronto, Ontario

Work: 416-488-2345
Fax: 416-488-3765

Chief Financial Officer/Investor Relations

Kristina Hachey, CPA

Theralase Technologies Inc.

41 Hollinger Road,
Toronto, Ontario

Investor Information

Data last updated on October 1, 2020

Theralase® Inc. is a subsidiary of Theralase® Technologies Inc., and is publicly traded on the
  • TSX Venture Exchange (TSXV: TLT)
  • Over-The-Counter Exchange (OTCQB: TLTFF)
Number of common shares outstanding

Share Price: C$0.14

Warrants: 72,473,931

Shares Outstanding: 204,275,375

Stock Options: 14,500,000

Fully Diluted: 291,249,306

For Investor Relations please contact: Investor Information Theralase®

Our Partners

As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies, Theralase® has partnered with individuals and groups at the following institutions and organizations.